Blog

Akash Maniam: The optimal management of upper tract urothelial carcinoma is far from clear

Photo from Akash Maniam/LinkedIn

Apr 27, 2024, 11:39

Akash Maniam: The optimal management of upper tract urothelial carcinoma is far from clear

Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post by International Urology Cancer Summit on LinkedIn, adding:

“Great question. The optimal management of upper tract urothelial carcinoma is far from clear. Higher fibroblast growth factor receptors (FGFR) alteration rates, lower immunotherapy response rates, differences in tumour mutational burden/microenvironment etc.

How do you or would you treat this at your centre? Chemotherapy alone, chemotherapy and IO, enfortumab-vedotin/Pembrolizumab

Would you enrol into a clinical trial example targeting Fibroblast growth factor receptor (FGFR) 1st line? Vote and comment, would be an enriching discussion!”

Quoting International Urology Cancer Summit’s post:

Akash Maniam cancer FGFR fibroblast growth factor receptors International Urology Cancer Summit OncoDaily Oncology pembrolizumab upper tract urothelial carcinoma

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding